Author(s): Diana Laila Ramatillah, Nona Ainah, Michael, Fauzi Kasim, Purwati, Kashifullah Khan


DOI: 10.52711/0974-360X.2023.00623   

Address: Diana Laila Ramatillah1, Nona Ainah1, Michael1, Fauzi Kasim1, Purwati1, Kashifullah Khan2
1Faculty of Pharmacy, Universitas 17 Agustus 1945 Jakarta 14350, Indonesia.
2Department of Clinical Pharmacy, University of Hail, Saudi Arabia.
*Corresponding Author

Published In:   Volume - 16,      Issue - 8,     Year - 2023

D-Dimer is a fibrin degradation product as the resultof thrombus degradation by fibrinolysis. Elevated D-dimer in the blood is a presumptive marker of thrombosis. D-dimer levels above 1g/mL are risk factors for poorprognosis in patients with COVID-19. To evaluate the impact of high D-Dimer on the clinical outcome of Covid-19 patients at Private Hospital in Jakarta. A retrospective cohort study with convenience sampling was applied in this study. There were 980 patients but only 320 patients were eligible for inclusion criteria. This study only included confirmed COVID-19 patients who were hospitalized from March to June 2021, and the study was conducted from March to June 2022. The gender of the majority patients as the sample was male, 165 (52%) and 155(48%) female patients with moderate severity. Correlation between D-dimer and clinical outcome of COVID-19 patients using Fisher's exact method showed a higher survival rate of 287(89.7%) patients compared to 33(10.3%) patients who died with a p-value <0.05. The survival analysis for COVID-19 patients using the Kaplan Meier method showed that patients receiving D-dimer <500ng/mL had a median survival rate of about 90% after approximately 21 days of treatments, whereas patients whowere receiving >500 ng/mL had a 50% survival rate after 30 days of treatment. Patients receiving D-dimer <500ng/mL had a survival rate of about 90% after undergoing treatment for approximately 21 days, while patients who had D-dimer>500 ng/mL had a survival rate of about 50% after 30 days of treatment. Anticoagulants were given to almost all patients, roughly 10 percent died during hospitalization with hypercoagulation complications.

Cite this article:
Diana Laila Ramatillah, Nona Ainah, Michael, Fauzi Kasim, Purwati, Kashifullah Khan. The Impact of High D-Dimer on The Clinical Outcome of Covid-19 patients at A Private Hospital in Jakarta. Research Journal of Pharmacy and Technology. 2023; 16(8):3773-9. doi: 10.52711/0974-360X.2023.00623

Diana Laila Ramatillah, Nona Ainah, Michael, Fauzi Kasim, Purwati, Kashifullah Khan. The Impact of High D-Dimer on The Clinical Outcome of Covid-19 patients at A Private Hospital in Jakarta. Research Journal of Pharmacy and Technology. 2023; 16(8):3773-9. doi: 10.52711/0974-360X.2023.00623   Available on:

1.    World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it [Internet]. 2020 [cited 2022 Jun 18]. Available from:
2.    Hechhu R, Vasanthi R, BalchaBalla T, J K. Current clinical anticipation of Arbidol against COVID-19: Possibilities. Res J Pharm Technol. 2022; 15(3):1653–8. 10.52711/0974-360X.2022.00276    
3.    Bhattacharjee A, RandhoniChanu N, Bhattacharya K. COVID-19 Pandemic: A Pragmatic plan for Therapeutic Intervention. Res J Pharm Technol. 2022; 5(5):2862–8.  10.52711/0974-360X.2022.00478
4.    Ahmad S, Shoaib A, Ali MdS, AlamMdS, Alam N, Ali M, et al. Epidemiology, risk, myths, pharmacotherapeutic management and socio economic burden due to novel COVID-19: A recent update. Res J Pharm Technol. 2020;13(9):4435.10.5958/0974-360X.2020.00784.2
5.    Al-Hamamy HR. COVID-19: Immune response. Res J Pharm Technol. 2022 Jan 25;467–70. 10.52711/0974-360X.2022.00076
6.    Worldometers. Coronavirus Pandemic [Internet]. 2021 [cited 2021 Nov 14]. Available from:
7.    Arnanda N, Ramatillah DL. Systematic Review: Evaluation Of Cytokine Storm Treatment From COVID 19 Patient Base On Clinical Trial. International Journal of Applied Pharmaceutics. 2022; 1:5–9.
8.    Alaraj M. Pharmacological repurposed agents for COVID-19. Res J Pharm Technol. 2022; 15(1): 441–6. 10.52711/0974-360X.2022.00073
9.    Zhan H, Chen H, Liu C, Cheng L, Yan S, Li H, et al. Diagnostic Value of D-Dimer in COVID-19: A Meta-Analysis and Meta-Regression. Clinical and Applied Thrombosis/Hemostasis. 2021 Jan 1;27:107602962110109. 10.1177/10760296211010976
10.    Terpos E, Ntanasis‐Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID‐19. Am J Hematol. 2020; 95(7):834–47. 10.1002/ajh.25829
11.    Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. 2020 Dec 10;8(1):49.
12.    Marietta M, Ageno W, Artoni A, de Candia E, Gresele P, Marchetti M, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2020;18(3):167–9. 10.2450/2020.0083-20
13.    Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associated with the severity of COVID-19. Thromb Res. 2020;195:219–25. 10.1016/j.thromres.2020.07.047
14.    Rokade M, Khandagale P. Coronavirus disease: A review of a new threat to public health. Asian Journal of Pharmaceutical Research. 2020;10(3):241. 10.5958/2231-5691.2020.00042.8
15.    Guan W jie, Ni Z yi, Hu Y, Liang W hua, Ou C quan, He J xing, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708–20. 10.1056/NEJMoa2002032
16.    Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020; 18(6): 1324–9.  10.1111/jth.14859
17.    Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054–62.
18.    Michael, Ramatillah DL. Treatment Profile And Survival Analysis Acute Respiratory Distress Syndrome (ARDS) COVID-19 Patients. International Journal of Applied Pharmaceutics. 2022; 14(Special Issue 2).
19.    Ramatillah DL, Gan SH, Sulaiman SAS, Puja D, Abubakar U, Jaber AAS, et al. Evaluation of Treatment Outcome for Pneumonia among Pre-Vaccinated COVID-19 Patients with/without Comorbidity in a Public Hospital in Bengkulu, Indonesia. Vaccines (Basel). 2021; 9(12): 1411. 10.3390/vaccines9121411
20.    Force IC-19 HT. Distribution Map [Internet]. 2020 [cited 2022 Feb 18]. Available from:
21.    Ramatillah DL, Isnaini S. Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. PLoS One. 2021; 16(4): e0250147.
22.    Vesselaldo M, Ramatillah DL. Evaluation Of BMI Relationship With Increased D-Dimer In COVID-19 Patients At A Jakarta Private Hospital. International Journal of Applied Pharmaceutics. 2022;49–53.
23.    ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021;385(9): 790–802. 10.1056/NEJMoa2105911
24.    Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. Expert Rev Hematol. 2020; 13(11):1265–75.  10.1080/17474086.2020.1831383
25.    Berger JS, Kunichoff D, Adhikari S, Ahuja T, Amoroso N, Aphinyanaphongs Y, et al. Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19. Arterioscler Thromb Vasc Biol. 2020; 40(10):2539–47. 10.1161/ATVBAHA.120.314872
26.    He X, Yao F, Chen J, Wang Y, Fang X, Lin X, et al. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. Sci Rep. 2021; 11(1): 1830.
27.    Mor S, Saini P, Wangnoo SK, Bawa T. Worldwide spread of COVID-19 Pandemic and risk factors among Co-morbid conditions especially Diabetes Mellitus in India. Res J Pharm Technol. 2020;13(5):2530. 10.5958/0974-360X.2020.00450.3
28.    Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(6): 1421–4.  10.1111/jth.14830
29.    Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4): 844–7.  10.1111/jth.14768
30.    Ullah W, Thalambedu N, Haq S, Saeed R, Khanal S, Tariq S, et al. Predictability of CRP and D-Dimer levels for in-hospital outcomes and mortality of COVID-19. J Community Hosp Intern Med Perspect. 2020 ;10(5): 402–8. 10.1080/20009666.2020.1798141
31.    Gungor B, Atici A, Baycan OF, Alici G, Ozturk F, Tugrul S, et al. Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: A systematic review and meta-analysis. Am J Emerg Med. 2021;39:173–9. 10.1016/j.ajem.2020.09.018
32.    Komiyama M, Hasegawa K. Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness. Eur Cardiol. 2020 ;15:e58. 10.15420/ecr.2020.24
33.    Kementerian Kesehatan RI. PedomanInterpretasi Data Klinik [Internet]. 2020 [cited 2022 May 18]. Available from:
34.    Dey J, Mukherjee S. Wireless COVID-19 Telehealth: Leukocytes Encryption Guided by Amino Acid Matrix. WirelPersCommun. 2021;120(2): 1769–89. 10.1007/s11277-021-08534-9
35.    Kaya T, Nalbant A, Kılıçcıoğlu GK, Çayır KT, Yaylacı S, Varım C. The prognostic significance of erythrocyte sedimentation rate in COVID-19. Rev Assoc Med Bras (1992). 2021 ;67(9):1305–10. 10.1590/1806-9282.20210618
36.    Chedid M, Waked R, Haddad E, Chetata N, Saliba G, Choucair J. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. J Infect Public Health. 2021; 14(5): 570–6. 10.1016/j.jiph.2021.02.001
37.    Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020; 395(10223): 507–13.
38.    Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(4):e208857. 10.1001/jamanetworkopen.2020.8857
39.    Saber S, Khodir AE, Maghmomeh AO, Nouh NA, El-Baz AM. COVID-19 Pandemic: current Challenges and future Perspectives. Res J Pharm Technol. 2022; 15(1): 329–37.
40.    Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis. 2020;18(5):1094–9. 10.1111/jth.14817
41.    Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(5): 1023–6.  10.1111/jth.14810
42.    Yee MM, Khaing MM, Yee KT, Thidar AM. A brief review on pregnancy risk reasoned to COVID-19. Res J Pharm Technol. 2022; 15(1): 424–8. 10.52711/0974-360X.2022.00070   
43.    Thai PQ, Toan DTT, Son DT, Van HTH, Minh LN, Hung LX, et al. Factors associated with the duration of hospitalisation among COVID-19 patients in Vietnam: A survival analysis. Epidemiol Infect. 2020;148:e114. 10.1017/S0950268820001259
44.    Wang Z, John SJ, Liu Y, Liu R, Zha Y, Chang X, et al. Survival analysis of hospital length of stay of novel coronavirus (COVID-19) pneumonia patients in Sichuan, China. Medrxiv [Internet]. 2020; Available from:

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available